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Erratum
Predictors of Outcomes after Surgical Treatment of Synchronous Primary Lung Cancers: Erratum
In the article that appeared on page 197 of the February 2010 issue, an acknowledgement that should have appeared with
Table 4 was inadvertently omitted. The acknowledgment should have appeared as follows:
The authors are grateful to Dr. Nicolas Girard (Sloan-Kettering Institute) for the use of this table.
This error has been noted in the online version of the article, which is available at www.jto.org.
Reference:
Finley DJ, Yoshizawa A, Travis W, et al. Predictors of Outcomes after Surgical Treatment of Synchronous Primary Lung
Cancers. J Thorac Oncol. 2010;5:197–205.
Erratum
Osteoblastic Response in Patients with Non-small Cell Lung Cancer with Activating EGFR Mutations and Bone
Metastases during Treatment with EGFR Kinase Inhibitors: Erratum
In the article that appeared on page 407 of the March 2010 issue, the disclosure statement was incorrect. The disclosure
should have appeared as follows:
Roman Thomas received research support from AstraZeneca and lecture fees from Roche. Ju¨rgen Wolf received research
support and served as a consultant to Roche and AstraZeneca. The authors’ employing organization received a grant from
Roche for clinical research.
This error has been noted in the online version of the article, which is available at www.jto.org.
Reference:
Anse´n S, Bangard C, Querings S, et al. Osteoblastic Response in Patients with Non-small Cell Lung Cancer with
Activating EGFR Mutations and Bone Metastases during Treatment with EGFR Kinase Inhibitors. J Thorac Oncol.
2010;5:407–409
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